



**HAL**  
open science

## Novel functions of the $\alpha$ -ketoglutarate dehydrogenase complex may mediate diverse oxidant-induced changes in mitochondrial enzymes associated with Alzheimer's disease

Qingli Shi, H. Xu, Wayne A. Kleinman, Gary E. Gibson

► **To cite this version:**

Qingli Shi, H. Xu, Wayne A. Kleinman, Gary E. Gibson. Novel functions of the  $\alpha$ -ketoglutarate dehydrogenase complex may mediate diverse oxidant-induced changes in mitochondrial enzymes associated with Alzheimer's disease. *Biochimica et Biophysica Acta - Molecular Basis of Disease*, 2008, 1782 (4), pp.229. 10.1016/j.bbadis.2007.12.008 . hal-00562815

**HAL Id: hal-00562815**

**<https://hal.science/hal-00562815>**

Submitted on 4 Feb 2011

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

## Accepted Manuscript

Novel functions of the  $\alpha$ -ketoglutarate dehydrogenase complex may mediate diverse oxidant-induced changes in mitochondrial enzymes associated with Alzheimer's disease

Qingli Shi, Hui Xu, Wayne A. Kleinman, Gary E. Gibson

PII: S0925-4439(07)00236-0  
DOI: doi: [10.1016/j.bbadis.2007.12.008](https://doi.org/10.1016/j.bbadis.2007.12.008)  
Reference: BBADIS 62773

To appear in: *BBA - Molecular Basis of Disease*

Received date: 11 September 2007  
Revised date: 7 December 2007  
Accepted date: 12 December 2007



Please cite this article as: Qingli Shi, Hui Xu, Wayne A. Kleinman, Gary E. Gibson, Novel functions of the  $\alpha$ -ketoglutarate dehydrogenase complex may mediate diverse oxidant-induced changes in mitochondrial enzymes associated with Alzheimer's disease, *BBA - Molecular Basis of Disease* (2008), doi: [10.1016/j.bbadis.2007.12.008](https://doi.org/10.1016/j.bbadis.2007.12.008)

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

**Novel functions of the  $\alpha$ -ketoglutarate dehydrogenase complex may mediate diverse oxidant-induced changes in mitochondrial enzymes associated with Alzheimer's disease**

Qingli Shi, Hui Xu, Wayne A. Kleinman and Gary E. Gibson

Department of Neurology and Neuroscience, Weill Medical College of Cornell University/Burke Medical Research Institute, 785 Mamaroneck Ave., White Plains, New York 10605, USA

Address correspondence to: Gary E. Gibson, Dept. of Neurology and Neuroscience, Weill Medical College of Cornell University/Burke Medical Research Institute, 785 Mamaroneck Ave., White Plains, New York 10605, USA

Tel: 914-597-2291

Fax: 914-597-2757

E-Mail: [ggibson@med.cornell.edu](mailto:ggibson@med.cornell.edu)

**Keywords:**  $\alpha$ -ketoglutarate dehydrogenase complex; Alzheimer's disease; glutathione; malate dehydrogenase; reactive oxygen species.

**Abstract**

Measures in autopsied brains from Alzheimer's Disease (AD) patients reveal a decrease in the activity of  $\alpha$ -ketoglutarate dehydrogenase complex (KGDHC) and an increase in malate dehydrogenase (MDH) activity. The present experiments tested whether both changes could be caused by the common oxidant  $H_2O_2$  and to probe the mechanism underlying these changes. Since the response to  $H_2O_2$  is modified by the level of the E2k subunit of KGDHC, the interaction of MDH and KGDHC was studied in cells with varying levels of E2k. In cells with only 23% of normal E2k protein levels, one hour treatment with  $H_2O_2$  decreased KGDHC and increased MDH activity as well as the mRNA level for both cytosolic and mitochondrial MDH. The increase in MDH did not occur in cells with 100% or 46% of normal E2k. Longer treatments with  $H_2O_2$  inhibited the activity of both enzymes. Glutathione is a major regulator of cellular redox state and can modify enzyme activities.  $H_2O_2$  converts reduced glutathione (GSH) to oxidized glutathione (GSSG), which reacts with protein thiols. Treatment of purified KGDHC with GSSG leads to glutathionylation of all three KGDHC subunits. Thus, cellular glutathione level was manipulated by two means to determine the effect on KGDHC and MDH activities. Both buthionine sulfoximine (BSO), which inhibits glutathione synthesis without altering redox state, and  $H_2O_2$  diminished glutathione to a similar level after 24 hrs. However,  $H_2O_2$ , but not BSO, reduced KGDHC and MDH activities, and the reduction was greater in the E2k-23 line. These findings suggest that the E2k may mediate diverse responses of KGDHC and MDH to oxidants. In addition, the differential response of activities to BSO and  $H_2O_2$  together with the *in vitro* interaction of KGDHC with GSSG suggests that glutathionylation is one possible mechanism underlying oxidative stress-induced inhibition of the TCA cycle enzymes.

## Introduction

Diminished energy metabolism and enhanced oxidative stress [excess of reactive oxygen species (ROS) to antioxidants] are consistent features of Alzheimer's disease (AD) [1,2,3,4,5]. Recent studies on brains of patients that died with AD indicate a selective modification of the mitochondrial tricarboxylic acid (TCA) cycle, a major pathway of the oxidative metabolism. The TCA cycle consists of eight enzymes including the  $\alpha$ -ketoglutarate dehydrogenase complex (KGDHC, EC 1.2.4.2, EC 2.3.1.61, EC 1.6.4.3) and malate dehydrogenase (MDH, EC 1.1.1.37). The activity of KGDHC declines in AD [6,7,8,9,10,11,12], while MDH activity is elevated [13]. The mechanism of the diverse response of the TCA cycle enzyme in AD is unknown. Our previous studies suggest that oxidants can mimic the diverse changes that accompany AD. For example, hydrogen peroxide ( $H_2O_2$ ) mimics the increase in endoplasmic reticulum calcium stores and the decline in the activity of KGDHC [14].

KGDHC consists of three subunits [ $\alpha$ -ketoglutarate dehydrogenase (E1k), dihydrolipoyl succinyltransferase (E2k) and dihydrolipoyl dehydrogenase (E3)] and is a key and arguably rate-limiting enzyme in the TCA cycle [10]. Multiple copies of E1k (12 dimers) and E3 (6 dimers) are arranged along the edges and faces, respectively, of an octahedral E2k core (24 subunits) to form a multienzyme complex with a molecular weight of around  $5 \times 10^6$  dalton [15]. Diminished KGDHC activity occurs in both normal and pathologically involved brain areas of patients with a number of neurodegenerative diseases including AD, Parkinson's disease (PD), progressive supranuclear palsy and Wernicke-Korsakoff syndrome [6,10,11,12,16,17,18,19,20,21]. In AD patients the reduction in the activity of KGDHC is highly correlated to a clinical dementia rating (CDR) [13]. These results suggest that KGDHC may play a central role in the pathophysiology of the diseases. KGDHC is sensitive to a wide range of oxidants whether the oxidants are added

to the purified enzyme or cell system [22,23,24], or generated internally in cells or mice [25,26,27]. H<sub>2</sub>O<sub>2</sub> reduces KGDHC activity in fibroblasts, intact cardiac mitochondria, synaptosomes and N2a cells [22,23,28,29]. These results suggest that oxidative stress is one plausible link between diminished KGDHC activity and neurodegenerative diseases.

MDH, the final enzyme in the TCA cycle, catalyzes the interconversion of L-malate and oxaloacetate using nicotinamide adenine dinucleotide (NAD) as a cofactor (L-malate + NAD<sup>+</sup>  $\rightleftharpoons$  oxaloacetate + NADH + H<sup>+</sup>) [30]. Mammalian cells contain two isozymes of MDH: mitochondrial (m-MDH) and soluble or cytoplasmic (c-MDH). The two isozymes consist of two very similar subunits of about 35,000 daltons with similar enzymatic activity but appear to be different proteins [31]. Elevated MDH activity occurs under a number of conditions. For example, mice on a caloric restricted diet show increased MDH activity compared to mice on a normal diet [32]. Total MDH activity is also higher in autopsy brains from AD patients compared with brains from normal individuals [13]. However, the regulation of MDH and its relation to diminished KGDHC activity in the disease are unknown.

Glutathione, a tripeptide composed of L-glutamate, L-cysteine and glycine, is considered to be the most important endogenous intracellular antioxidant in mammalian cells [33,34]. Reduced (GSH) and oxidized (GSSG) forms of glutathione are interconvertible by the action of two enzymes, GSH peroxidase and GSSG reductase [35,36]. Altered glutathione metabolism has been observed in multiple neurodegenerative diseases [37,38,39]. For example, GSH declines by 40% in substantia nigra of PD patients [38]. Whether glutathione level is significantly reduced in AD remains unclear as many studies are contradictory at various levels. For example, the total brain levels of GSH appeared to be unaffected in AD [40,41], while GSH peroxidase (GSH-Px) and GSH reductase (GSH-R) are elevated in different brain regions [42]. Serum GSH-Px activity

is either decreased [43,44] or increased in AD [45]. Another study [37] compares total and protein-bound thiol levels in the hippocampus and cerebellum of six Alzheimer's disease (AD) patients and six age-matched control subjects. Total level of sulfhydryl (SH) groups is not significantly altered in the hippocampus and cerebellum of AD patients. The level of protein-bound SH groups decreases in the AD hippocampus compared with controls.  $H_2O_2$  induces accumulation of GSSG and GSSG can form mixed disulfides with cellular protein thiols or intraprotein disulfides which leads to altered enzyme functions [46]. Thus, altered glutathione redox state may mediate changes in the TCA cycle enzymes under oxidative stress through glutathionylation.

Glutathionylation of KGDHC is one possible mechanism underlying its inactivation by oxidative stress [47]. In addition to existence of multiple cysteine residues in the three subunits, a unique feature of KGDHC is that the E2k subunit has a bound lipoic acid that is cycled between thiol and disulfide forms during the catalysis. In non-genetic forms of AD, the immunoreactivity of E2k is significantly reduced by 23- 41% in the temporal cortex, while no changes in the E2k protein levels occur in the parietal cortex and hippocampus [48]. The E2k protein level is also diminished by 76% in brains of the APP670/671 (Swedish mutation) family [49]. Our previous study demonstrates that the response of cells to  $H_2O_2$  is modulated by the E2k and is independent of changes in activity of the complex [50]. Thus, the E2k subunit of KGDHC may have other novel functions in modulating oxidative stress-induced changes in the activities of the TCA cycle enzymes in AD.

Two HEK293 lines expressing E2k antisense RNA, in which E2k protein contents were reduced to 46% (E2k-46) and 23% (E2k-23) of a sense control line (E2k-100), were developed in our previous study [50]. The studies reveal that E2k modifies ROS production and cell death in

response to H<sub>2</sub>O<sub>2</sub>. The present experiments used these cell lines to test whether concentrations of H<sub>2</sub>O<sub>2</sub> that diminish KGDHC activity increase MDH activity and if the E2k of KGDHC modulates these changes. The experiments also tested whether GSSG directly interact with KGDHC *in vitro*, and whether manipulation of free glutathione level by buthionine sulfoximine (BSO, an inhibitor of glutathione synthesis) or H<sub>2</sub>O<sub>2</sub> correlates with changes in KGDHC and MDH activities.

## Experimental procedures

### *Cell cultures and treatments*

The E2k-46 and E2k-23 cell lines with half and three-quarters diminished E2k protein along with the control line (E2k-100) were generated previously [50]. “100”, “46” and “23” represent the protein level of the E2k in the E2k-100, E2k-46 and E2k-23 line, respectively [50]. They were grown in Dulbecco's Modified Eagle Medium (DMEM) (high glucose) supplemented with 10% (v/v) fetal bovine serum (FBS), penicillin (50 units/ml), streptomycin (50 µg/ml) and hygromycin (100 µg/ml), and incubated at 37°C in a humidified atmosphere of 5% CO<sub>2</sub> in air.

Cells grown in 100-mm cell culture dishes (~ 90% confluent) were trypsinized, counted and seeded into six 6-well plates per cell line at a density of 5x10<sup>4</sup> cells/well, and incubated at 37°C in a humidified atmosphere of 5% CO<sub>2</sub> in air. When near 80- 90% confluent, the cells were washed twice with phosphate buffered saline (PBS) buffer and treated for one or 24 hours with the treatments indicated in the figure legends. At the end of the each treatment, cells including any floating cells in each well were collected and harvested by centrifugation at 290 g for 5 min at 4°C. The supernatants were discarded and cell pellets were washed once with PBS buffer and kept on ice or stored at -80°C for further use.

*KGDHC activity assay*

KGDHC catalyzes the following reaction:  $\alpha$ -ketoglutarate + NAD<sup>+</sup> + CoA → succinyl CoA + CO<sub>2</sub> + NADH. The assay uses  $\alpha$ -ketoglutarate to distinguish KGDHC produced NADH from NADH generated by other enzymes. Cell pellets were lysed with 250  $\mu$ l of KGDHC lysis buffer, passed through a 1 ml syringe with a 27 gauge needle several times and KGDHC activities were assayed immediately as described previously [10].

*MDH activity assay*

MDH catalyzes the following reaction: L-malate + NAD<sup>+</sup>  $\rightleftharpoons$  oxaloacetate + NADH. The MDH activity was measured by an oxaloacetate-dependent NADH oxidation assay as described previously [13] with slight modifications. Briefly, cell pellets were lysed in 250  $\mu$ l of KGDHC lysis buffer [10] and passed through a 1 ml syringe with a 27 gauge needle several times. After incubation of the cell lysate at room temperature for 30 min, 20  $\mu$ l of blank (lysis buffer), standards and samples were added to wells of a 96-well plate followed by addition of 140  $\mu$ l of 100 mM potassium phosphate buffer (pH 7.2) and 20  $\mu$ l of 20 mM oxaloacetic acid. The reaction was initiated by adding 20  $\mu$ l of 10 mM NADH to the mixture. The plate was read at an excitation wavelength of 340 nm and an emission wavelength of 460 nm (cutoff 455 nm) at 25°C for 25 min using a SPECTRAmax GEMINI XS fluorescence micro-plate reader (Molecular Devices). The rate of NADH oxidation was corrected with NADH standard curve and normalized to protein contents as determined by a Bio-Rad protein assay based on the Bradford dye-binding method (Bio-Rad) using BSA as standard.

*Real-time PCR*

Total RNA was isolated from cells treated with H<sub>2</sub>O<sub>2</sub> (0.1 and 1 mM) for one hr using a RNeasy Mini kit (Qiagen, Valencia, CA) according to the supplier's instruction. This was

followed by first strand cDNA synthesis using the First Strand cDNA synthesis kit for RT-PCR (AMV) (Roche Applied Science, Indianapolis, IN) with oligo-p(dT)<sub>15</sub> as primer. Real-time PCR of cytoplasmic MDH (cMDH) and mitochondrial MDH (mMDH) was performed using an Applied Biosystems 7500 Real-Time PCR system with pre-designed Taqman® gene expression assays (Applied Biosystems, Foster City, CA). In brief, each amplification mixture (50 µl) contained 22.5 µl of cDNA template, 25 µl of TaqMan® Universal PCR Master Mix, 2.5 µl of a FAM™ dye labeled TaqMan® MGB probe and two PCR primers. Thermal cycler conditions were 95°C for 10 min, and 40 cycles of 95°C for 15 sec and 60°C for 1 min. All samples were normalized for beta-2-microglobulin (b2m) expression. A comparative *C<sub>t</sub>* (the threshold cycle of PCR at which amplified product was first detected) method was used to compare the mRNA expression in samples treated with H<sub>2</sub>O<sub>2</sub> to that of the untreated controls.

#### *GSSG treatment, SDS-PAGE and Western blotting*

KGDHC (Sigma) (200 µl) was loaded onto a 2% ABT Agarose column (Agarose Bead Technologies, Tampa, FL) to remove contaminating bovine serum albumin. Five of the fractions with the highest KGDHC activity from four column purifications were pooled and concentrated by Amicon Ultra-15 Centrifugal Filter Unit 100 (Millipore, Billerica, MA). Concentrated KGDHC was incubated with 0, 0.5 or 5 mM oxidized glutathione (GSSG) (Sigma, St. Louis, MO) in 100 mM phosphate buffer (PB) (pH 7.2) at 37°C for 30 min. At the end of incubation, 5X SDS-sample loading dye [50% glycerol, 250 mM Tris (pH 6.8), 10 mM EDTA, 10 % SDS and 0.04 % bromophenol blue] was added to the reaction mixture to achieve 1X final concentration. Electrophoresis was done with a 4-20% Tris-Glycine gel (Invitrogen; Carlsbad,

CA) using 120 volts for 2.5 hr. Separated proteins were then electrotransferred to a nitrocellulose membrane (Amersham Biosciences; Piscataway, NJ) using 45 volts for 3 hr. Blots were blocked with Tris-buffered saline (TBS)/Ody Blocking buffer (LI-COR Biosciences, Lincoln, NE) (1:1 in volume) at 4°C overnight, and incubated with rabbit E1k, E2k or E3 antibody and anti-glutathione antibody (Virogen, Watertown, MA) (1:1,000 dilution) at room temperature for 3.5 hr. After washing thoroughly with TBS/0.1% Tween-20 at room temperature, the blots were incubated with Odyssey Goat anti-rabbit IRDye680 antibody and goat anti-mouse IRDye800CW antibody at room temperature for 1 hr (1:5,000; LI-COR Biosciences, Lincoln, NE). After extensive washing, the membranes were scanned by the Odyssey Infrared Imaging System (LI-COR Biosciences, Lincoln, NE).

#### *Total free cellular glutathione measurement*

Cell pellets were deproteinized by the addition of 150 µl of 5% ice-cold metaphosphoric acid (v/v). The samples were vortexed, incubated at 4°C for 25 min and revortexed. Samples were then centrifuged at 10,000 g for 10 min (4°C) to separate supernatants from the pellets. The supernatants were carefully transferred to new 1.5 ml tubes without disturbing the pellets and stored at -20°C for glutathione measurement. The pellets were solubilized with 1 N NaOH and the protein concentrations were measured using a Bio-Rad protein assay based on the Bradford dye-binding method (Bio-Rad) using bovine serum albumin (BSA) as standard.

The supernatants containing free thiols were diluted 6 fold with 0.3 M assay buffer (100 mM NaH<sub>2</sub>PO<sub>4</sub> and 5 mM EDTA, pH 7.5). Total free glutathione was determined using a microplate method [51] based on the DTNB [5,5'-dithiobis-(2-nitrobenzoic acid)]/enzymatic recycling procedure [52,53]. In brief, 50 µl of GSH standard or diluted sample extract was added to the wells of a 96-well plate followed by addition of 50 µl each of 1.26 mM DTNB and 2.5

u/ml of glutathione reductase (Sigma). After incubation at room temperature for 15 min, the reaction was started by the addition of 50  $\mu$ l of 0.6 mg/ml of NADPH to each well. After addition of NADPH, the plate was immediately read in a SPECTRAMax microplate reader (Molecular Devices). The rate of change in absorbance at 410 nm was monitored for 3 min at 16-sec intervals. All standard and samples were run in duplicate in adjacent wells. Values were calculated with a GSH standard curve and normalized with protein contents measured by a Bio-Rad protein assay.

## Results

### *Response of KGDHC and MDH activities to 1 hr of H<sub>2</sub>O<sub>2</sub>*

Whether H<sub>2</sub>O<sub>2</sub> induces diverse changes of the KGDHC and MDH activities and whether E2k modulates these changes were tested in all three lines. H<sub>2</sub>O<sub>2</sub> diminished the KGDHC activity by 24 % in all lines (Figure 1A). The MDH activity is elevated by 16% in the E2k-23 line under normal conditions (Figure 1B). Interestingly, one hr of H<sub>2</sub>O<sub>2</sub> increased MDH activity by 15% but only in the E2k-23 line (Figure 1B).

### *One hr of H<sub>2</sub>O<sub>2</sub> elevated mRNA level of MDH*

The MDH activity measures include both cytosolic and mitochondrial MDH activities. Although activity measures cannot distinguish between mitochondrial and cytosolic MDH, the two forms can be readily distinguished at the message level. Relative quantitative Real-time PCR was used to examine the changes in the levels of mRNA of cytosolic MDH (cMDH) and mitochondrial MDH (mMDH). H<sub>2</sub>O<sub>2</sub> (1 hr) increased mRNA level of cMDH by 16% (0.1 mM H<sub>2</sub>O<sub>2</sub>) and 20% (1 mM H<sub>2</sub>O<sub>2</sub>) but only in the E2k-23 line (Figure 2A). Similarly, the mRNA

level of mMDH was also elevated by 25% in response to one hr of  $H_2O_2$  but only in the E2k-23 line (Figure 2B).

#### *Glutathionylation of KGDHC by GSSG*

Glutathionylation of KGDHC is postulated from previous study [22]. Thus, whether purified KGDHC interacts with GSSG was tested by Western blotting. Western blot of E1k (red)/glutathione (green) showed that treatment of KGDHC with increased concentration of GSSG induced glutathionylation of E1k (Figure 3A). Western blot of E2k (red)/glutathione (green) showed that the immunoreactivity of glutathione increased with the increased concentration of GSSG (Figure 3B). GSSG decreased the immunoreactivity of E3 and increased and shifted the glutathionylated E3 in a dose dependent manner (Figure 3C).

#### *Response of total free cellular glutathione levels to one hour of BSO, $H_2O_2$ or $H_2O_2$ /BSO*

Cellular free glutathione level was manipulated by two means. BSO diminished glutathione by blocking its synthesis.  $H_2O_2$  converts GSH to GSSG which binds to cellular proteins. One hour of BSO,  $H_2O_2$  or  $H_2O_2$ /BSO did not alter the total free cellular glutathione levels (GSH and GSSG) in any of the three lines (Figure 4). Furthermore, the reduction of E2k had no effect on the total free cellular glutathione levels (Figure 4).

#### *Response of KGDHC and MDH activities to one hour of BSO, $H_2O_2$ or $H_2O_2$ /BSO*

The effect of BSO,  $H_2O_2$  or  $H_2O_2$ /BSO on the KGDHC and MDH activities was tested. BSO did not alter either KGDHC or MDH activity in any line at any concentrations (Figure 5). Although no reduction in the total free cellular glutathione occurred at one hr treatment,  $H_2O_2$  diminished the KGDHC activity by 24 % in all lines (Figure 1A and Figure 5A). Moreover, one hr of  $H_2O_2$  increased MDH activity by 15% only in the E2k-23 line (Figure 1B and Figure 5B).

Addition of BSO did not enhance the changes in the KGDHC or MDH activity induced by H<sub>2</sub>O<sub>2</sub> (Figure 5).

*Response of total free cellular glutathione levels to 24 hour of BSO, H<sub>2</sub>O<sub>2</sub> or H<sub>2</sub>O<sub>2</sub>/BSO*

The total free cellular glutathione levels were measured in the three lines- E2k-100, E2k-46 and E2k-23 treated with BSO, H<sub>2</sub>O<sub>2</sub> or H<sub>2</sub>O<sub>2</sub>/BSO for 24 hr. Twenty-four hour treatment depleted the total free cellular glutathione level by 30% to 48% in all three lines (Figure 6). The reductions in the total free cellular glutathione levels did not differ statistically among the three lines. Thus, the reduction in E2k did not alter BSO or H<sub>2</sub>O<sub>2</sub>-induced changes in the total free cellular glutathione.

*Response of KGDHC and MDH activity to 24 hour of BSO, H<sub>2</sub>O<sub>2</sub> or H<sub>2</sub>O<sub>2</sub>/BSO*

Although total free cellular glutathione declined significantly after 24 hr of exposure to 1 or 10 mM BSO, the activity of neither KGDHC (Figure 7A) nor MDH (Figure 7B) was altered in response to BSO. Twenty-four hour of H<sub>2</sub>O<sub>2</sub> reduced the KGDHC activity greater in the E2k-46 (-60 %) and E2k-23 (-64 %) lines than in the E2k-100 control line (-45 %) (Figure 7A). Addition of BSO did not enhance the changes in the KGDHC activity induced by H<sub>2</sub>O<sub>2</sub> (Figure 7A).

Similarly, twenty-four hour of H<sub>2</sub>O<sub>2</sub> reduced the MDH activity greater in the E2k-23 line (-73%) than in the E2k-100 (-56%) or the E2k-46 (-55%) lines (Figure 7B). BSO did not enhance the changes in MDH activity induced by H<sub>2</sub>O<sub>2</sub> (Figure 7B).

## **Discussion**

Diverse changes in the KGDHC and MDH activities occur in AD brain [13]. The underlying mechanism of these changes in AD is unknown. Our data shows that a short exposure of cells to H<sub>2</sub>O<sub>2</sub> diminished KGDHC activity and increased MDH activity. While the decrease in

KGDHC was independent of E2k, the increased MDH occurred only in the E2k-23 line in which the E2k is reduced by more than 75%. Thus, one hour exposure of cells with one common oxidant, H<sub>2</sub>O<sub>2</sub> (1 mM), can mimic the diminished KGDHC and increased MDH that occur in AD brain. In AD brains, both changes in the KGDHC (-57%) and MDH (+54%) activities are highly correlated with clinical dementia rating (CDR) score [13], suggesting that the diverse change in the KGDHC and MDH activities occurs after a chronic progression of the disease. Thus, it is likely that treatments of cells with lower dosages of oxidants over a longer period of time may better mimic AD chronic situation. Further, the effectiveness of H<sub>2</sub>O<sub>2</sub> on MDH is modified by the levels of E2k protein. H<sub>2</sub>O<sub>2</sub> also exaggerates the endoplasmic reticulum calcium content, another characteristic of cells from AD patient [14]. Thus, the data supports the possibility that multiple changes in AD maybe induced by specific oxidants.

The H<sub>2</sub>O<sub>2</sub>-induced increase in MDH is at least partly due to alterations in transcription. Increased MDH activity by H<sub>2</sub>O<sub>2</sub> (1 hr) in the E2k-23 line is associated with the elevated mRNA levels of both cytosolic and mitochondrial MDH. H<sub>2</sub>O<sub>2</sub> increases DCF-detectable reactive oxygen species (ROS) generation more in the E2k-23 line than in either the E2k-100 or E2k-46 line [50]. Oxidative stress up-regulates redox sensitive transcription factors such as activator protein 1 (AP-1) [54]. The potential binding site of AP-1 is predicted in the MDH promoter region. Thus, it is possible that the greater increase in ROS in the E2k-23 line may act on transcription of MDH which may lead to the increase in the MDH activity. Further studies on transcriptional regulation of MDH are necessary to explore the mechanism of elevated MDH activity in response to diminished E2k at early stages of oxidative stress.

Glutathione, a major free radical scavenger, is diminished in a number of neuro-degenerative diseases [55,56,57]. Depletion of glutathione has been associated with inhibition of

mitochondrial complex I, II, III and IV activities in neuronal cells [58], and is hypothesized to be an initial factor in oxidative stress-mediated neurodegeneration [59]. The oxidative stress that is associated with neurodegenerative diseases including AD may initiate an interaction of glutathione with metabolically important mitochondrial enzymes. For example, mitochondrial NADP<sup>+</sup>-dependent isocitrate dehydrogenase (IDPm) activity is inactivated through glutathionylation [60]. The activity of this enzyme is also diminished in brains from AD patients [13]. The present study on the interaction of purified KGDHC with GSSG demonstrated that glutathionylation can occur in all three subunits of KGDHC. This suggests that the stimulation of GSSG formation by oxidative stress may modulate KGDHC and modify its normal function.

To test the possible regulation of KGDHC by glutathionylation in cells, the level of free glutathione was manipulated by treating cells with either BSO or H<sub>2</sub>O<sub>2</sub> and the consequences on KGDHC and MDH activities were tested. Total free cellular glutathione was not diminished by one hour treatment with either BSO or H<sub>2</sub>O<sub>2</sub>. Nevertheless, the possible interaction of KGDHC with glutathione following H<sub>2</sub>O<sub>2</sub> cannot be excluded. Isolated KGDHC is inhibited only by high concentrations of H<sub>2</sub>O<sub>2</sub> (10 mM) [22]. Lower concentrations of H<sub>2</sub>O<sub>2</sub> do not affect the isolated enzyme or detergent-solubilized mitochondria, but do inhibit KGDHC in intact mitochondria [47] and in mammalian cells [23]. These data suggest that inactivation of KGDHC activity is not due to the direct interaction of peroxide with the enzyme, but is through redox-sensitive mechanism(s). Redox-regulated glutathionylation or deglutathionylation is one possible mechanism to account for the inactivation of KGDHC by H<sub>2</sub>O<sub>2</sub> [41]. H<sub>2</sub>O<sub>2</sub>, but not BSO, diminished KGDHC activity. H<sub>2</sub>O<sub>2</sub> causes accumulation of oxidized glutathione (GSSG) that can further form mixed disulfide with cellular protein thiols or intraprotein disulfides [61,62,63,64]. Formation of an intraprotein disulfide is more common when there are adjacent protein thiols

[65,66]. The unique feature of E2k is its bound lipoic acid with adjacent sulfhydryl groups that is cycled between thiol and disulfide bond during catalysis. Thus, it is likely that initial glutathionylation of KGDHC occurs at the E2k subunit and is only transient as its adjacent thiol displaces the GS<sup>-</sup> to form an intraprotein disulfide (reaction 1, Figure 8). In addition, another E2k intermediate [E2k•Lip(SCoR)(SH)] can react with GSSG and form E2k•Lip(SCoR)(S-SG) (reaction 2, Figure 8) which can further react with [E2k•Lip(SCoR)(SH)] (reaction 3, Figure 8). Therefore, at early stages of oxidative stress, interaction of GSSG with the E2k of KGDHC would be expected to limit NADH production and reduce KGDHC activity without alteration of glutathione level.

Although the 24-hour treatment with BSO or H<sub>2</sub>O<sub>2</sub> reduced the total free cellular glutathione level similarly in all lines, H<sub>2</sub>O<sub>2</sub>, but not BSO, diminished both KGDHC and MDH activities significantly. In addition, H<sub>2</sub>O<sub>2</sub> reduced both KGDHC and MDH activities most dramatically in the E2k-23 line compared to the other two lines. It is known that the GSH/GSSG ratio can be buffered by reaction of GSSG with cellular proteins to liberate one (reaction I) or two GSH (reaction II).



The E1k, E2k or E3 subunit of KGDHC contain 21, 6 or 10 cysteine residues, respectively. Similar reduction of the total free cellular glutathione in all lines induced by 24 hr of H<sub>2</sub>O<sub>2</sub> could be a result of glutathionylation of proteins including the three subunits of KGDHC. This reaction with E2k would be in addition to its transient interaction with the E2k of KGDHC. The level of E2k would then become a limiting factor upon its formation of intraprotein disulfide mediated by GSSG. Therefore, greater reduction of the KGDHC activity in the E2k diminished cells may

occur as observed in the E2k-46 and E2k-23 lines. Moreover, immunoblotting studies on the interaction of purified KGDHC with GSSG provided another piece of evidence that glutathionylation can occur in all three subunits of the complex. Taken together, our findings indicate that glutathione interacts with KGDHC under H<sub>2</sub>O<sub>2</sub>-induced oxidative stress and that this may account for the decline in activity. Furthermore, other mechanisms are also likely to contribute to the inhibition. For example, under pathological conditions in which cytosolic Ca<sup>2+</sup> is greatly elevated, mitochondrial Ca<sup>2+</sup> may reach levels that will inactivate KGDHC [14,67].

Oxidative stress-induced glutathionylation of MDH may contribute to the diminished activity in cells treated with H<sub>2</sub>O<sub>2</sub> (24 hr). MDH has been shown to be glutathionylated during oxidative stress [68], and it is inactivated by GSSG (our unpublished data). Inhibition of KGDHC by H<sub>2</sub>O<sub>2</sub> limits the amount of reducing equivalents NADH [69]. NADPH is an essential reducing equivalent for both regeneration of GSH by glutathione reductase and NADPH-dependent Trx system which are two important antioxidant defense systems. NADPH can be generated through NADP linked malic enzyme, NADP linked isocitrate dehydrogenase or nicotinamide nucleotide transhydrogenase. Latter converts NADH to NADPH when an increased demand is imposed by H<sub>2</sub>O<sub>2</sub> [69,70]. Thus, less amount of NADH available in the E2k-23 line induced by H<sub>2</sub>O<sub>2</sub> would further exaggerate oxidative stress and give rise to more profound loss of the MDH activity (-73%).

In summary, at one hr treatment, concentrations of H<sub>2</sub>O<sub>2</sub> that diminished KGDHC activity increased MDH activity. The results mimic the changes found in AD. The response of KGDHC and MDH activities to H<sub>2</sub>O<sub>2</sub> was altered by the E2k levels. These findings suggest that the E2k component of KGDHC may mediate diverse responses of KGDHC and other TCA cycle enzymes to oxidants. In addition, the differential response of activities to BSO and H<sub>2</sub>O<sub>2</sub> together

with the *in vitro* interaction of KGDHC with GSSG suggests that glutathionylation is one possible mechanism underlying inhibition of the TCA cycle enzymes under oxidative stress.

### Acknowledgments

\*This work was supported by NIH grants AG14600, AG11921 and AG14930.

### References

- [1] S.I. Rapoport, B. Horwitz, C.L. Grady, J.V. Haxby, C. DeCarli, M.B. Schapiro. Abnormal brain glucose metabolism in Alzheimer's disease, as measured by position emission tomography, *Adv Exp Med Biol*, 291, (1991) 231-48.
- [2] D.F. Benson, D.E. Kuhl, R.A. Hawkins, M.E. Phelps, J.L. Cummings, S.Y. Tsai. The fluorodeoxyglucose 18F scan in Alzheimer's disease and multi-infarct dementia, *Arch Neurol*, 40, (1983) 711-4.
- [3] W.R. Markesbery, J.M. Carney. Oxidative alterations in Alzheimer's disease, *Brain Pathol*, 9, (1999) 133-46.
- [4] G.S. Smith, M.J. de Leon, A.E. George, A. Kluger, N.D. Volkow, T. McRae, J. Golomb, S.H. Ferris, B. Reisberg, J. Ciaravino, a.l. et. Topography of cross-sectional and longitudinal glucose metabolic deficits in Alzheimer's disease. Pathophysiologic implications, *Arch Neurol*, 49, (1992) 1142-50.
- [5] M.A. Smith, C.A. Rottkamp, A. Nunomura, A.K. Raina, G. Perry. Oxidative stress in Alzheimer's disease, *Biochim Biophys Acta*, 1502, (2000) 139-44.
- [6] R.F. Butterworth, A.M. Besnard. Thiamine-dependent enzyme changes in temporal cortex of patients with Alzheimer's disease, *Metab Brain Dis*, 5, (1990) 179-84.
- [7] U. Krugel, V. Bigl, K. Eschrich, M. Bigl. Deafferentation of the septo-hippocampal pathway in rats as a model of the metabolic events in Alzheimer's disease, *Int J Dev Neurosci*, 19, (2001) 263-77.
- [8] E.K. Perry, R.H. Perry, B.E. Tomlinson, G. Blessed, P.H. Gibson. Coenzyme A-acetylating enzymes in Alzheimer's disease: possible cholinergic 'compartment' of pyruvate dehydrogenase, *Neurosci Lett*, 18, (1980) 105-10.
- [9] S. Sorbi, E.D. Bird, J.P. Blass. Decreased pyruvate dehydrogenase complex activity in Huntington and Alzheimer brain, *Ann Neurol*, 13, (1983) 72-8.
- [10] G.E. Gibson, K.F. Sheu, J.P. Blass, A. Baker, K.C. Carlson, B. Harding, P. Perrino.

- Reduced activities of thiamine-dependent enzymes in the brains and peripheral tissues of patients with Alzheimer's disease, *Arch Neurol*, 45, (1988) 836-40.
- [11] F. Mastrogiamco, C. Bergeron, S.J. Kish. Brain alpha-ketoglutarate dehydrogenase complex activity in Alzheimer's disease, *J Neurochem*, 61, (1993) 2007-14.
- [12] D. Terwel, J. Bothmer, E. Wolf, F. Meng, J. Jolles. Affected enzyme activities in Alzheimer's disease are sensitive to antemortem hypoxia, *J Neurol Sci*, 161, (1998) 47-56.
- [13] P. Bubber, V. Haroutunian, G. Fisch, J.P. Blass, G.E. Gibson. Mitochondrial abnormalities in Alzheimer brain: mechanistic implications, *Ann Neurol*, 57, (2005) 695-703.
- [14] G.E. Gibson, H. Zhang, H. Xu, L.C. Park, T.M. Jeitner. Oxidative stress increases internal calcium stores and reduces a key mitochondrial enzyme, *Biochim Biophys Acta*, 1586, (2002) 177-89.
- [15] F.H. Pettit, L. Hamilton, P. Munk, G. Namihira, M.H. Eley, C.R. Willms, L.J. Reed. Alpha-keto acid dehydrogenase complexes. XIX. Subunit structure of the *Escherichia coli* alpha-ketoglutarate dehydrogenase complex, *J Biol Chem*, 248, (1973) 5282-90.
- [16] G.E. Gibson, A.E. Kingsbury, H. Xu, J.G. Lindsay, S. Daniel, O.J. Foster, A.J. Lees, J.P. Blass. Deficits in a tricarboxylic acid cycle enzyme in brains from patients with Parkinson's disease, *Neurochem Int*, 43, (2003) 129-35.
- [17] F.J. Jimenez-Jimenez, J.A. Molina, A. Hernanz, E. Fernandez-Vivancos, F. de Bustos, B. Barcenilla, C. Gomez-Escalonilla, M. Zurdo, A. Berbel, C. Villanueva. Cerebrospinal fluid levels of thiamine in patients with Parkinson's disease, *Neurosci Lett*, 271, (1999) 33-6.
- [18] Y. Mizuno, S. Matuda, H. Yoshino, H. Mori, N. Hattori, S. Ikebe. An immunohistochemical study on alpha-ketoglutarate dehydrogenase complex in Parkinson's disease, *Ann Neurol*, 35, (1994) 204-10.
- [19] L.C. Park, D.S. Albers, H. Xu, J.G. Lindsay, M.F. Beal, G.E. Gibson. Mitochondrial impairment in the cerebellum of the patients with progressive supranuclear palsy, *J Neurosci Res*, 66, (2001) 1028-34.
- [20] D.S. Albers, S.J. Augood, L.C. Park, S.E. Browne, D.M. Martin, J. Adamson, M. Hutton, D.G. Standaert, J.P. Vonsattel, G.E. Gibson, M.F. Beal. Frontal lobe dysfunction in progressive supranuclear palsy: evidence for oxidative stress and mitochondrial impairment, *J Neurochem*, 74, (2000) 878-81.
- [21] R.F. Butterworth, J.J. Kril, C.G. Harper. Thiamine-dependent enzyme changes in the brains of alcoholics: relationship to the Wernicke-Korsakoff syndrome, *Alcohol Clin Exp Res*, 17, (1993) 1084-8.
- [22] T.M. Jeitner, H. Xu, G.E. Gibson. Inhibition of the alpha-ketoglutarate dehydrogenase complex by the myeloperoxidase products, hypochlorous acid and mono-N-chloramine, *J Neurochem*, 92, (2005) 302-10.

- [23] G.E. Gibson. Interactions of oxidative stress with cellular calcium dynamics and glucose metabolism in Alzheimer's disease, *Free Radic Biol Med*, 32, (2002) 1061-70.
- [24] K.M. Humphries, L.I. Szweda. Selective inactivation of alpha-ketoglutarate dehydrogenase and pyruvate dehydrogenase: reaction of lipoic acid with 4-hydroxy-2-nonenal, *Biochemistry*, 37, (1998) 15835-41.
- [25] L.C. Park, H. Zhang, K.F. Sheu, N.Y. Calingasan, B.S. Kristal, J.G. Lindsay, G.E. Gibson. Metabolic impairment induces oxidative stress, compromises inflammatory responses, and inactivates a key mitochondrial enzyme in microglia, *J Neurochem*, 72, (1999) 1948-58.
- [26] K.F. Sheu, N.Y. Calingasan, J.G. Lindsay, G.E. Gibson. Immunochemical characterization of the deficiency of the alpha-ketoglutarate dehydrogenase complex in thiamine-deficient rat brain, *J Neurochem*, 70, (1998) 1143-50.
- [27] R.F. Butterworth, J.F. Giguere, A.M. Besnard. Activities of thiamine-dependent enzymes in two experimental models of thiamine-deficiency encephalopathy. 2. alpha-Ketoglutarate dehydrogenase, *Neurochem Res*, 11, (1986) 567-77.
- [28] A.C. Nulton-Persson, L.I. Szweda. Modulation of mitochondrial function by hydrogen peroxide, *J Biol Chem*, 276, (2001) 23357-61.
- [29] C. Chinopoulos, L. Tretter, V. Adam-Vizi. Depolarization of in situ mitochondria due to hydrogen peroxide-induced oxidative stress in nerve terminals: inhibition of alpha-ketoglutarate dehydrogenase, *J Neurochem*, 73, (1999) 220-8.
- [30] D. Dupourque, E. Kun. Malate dehydrogenases of ox kidney. 2. Two substrate kinetic and inhibition analyses, *Eur J Biochem*, 7, (1969) 247-52.
- [31] D.M. Bleile, M. Foster, J.W. Brady, J.H. Harrison. Identification of essential arginyl residues in cytoplasmic malate dehydrogenase with butanedione, *J Biol Chem*, 250, (1975) 6222-7.
- [32] K. Hagopian, J.J. Ramsey, R. Weindruch. Krebs cycle enzymes from livers of old mice are differentially regulated by caloric restriction, *Exp Gerontol*, 39, (2004) 1145-54.
- [33] R. Dringen. Metabolism and functions of glutathione in brain, *Prog Neurobiol*, 62, (2000) 649-71.
- [34] A. Meister. Glutathione metabolism and its selective modification, *J Biol Chem*, 263, (1988) 17205-8.
- [35] M. Toborek, B. Hennig. Fatty acid-mediated effects on the glutathione redox cycle in cultured endothelial cells, *Am J Clin Nutr*, 59, (1994) 60-5.
- [36] S.M. Deneke, B.L. Fanburg. Regulation of cellular glutathione, *Am J Physiol*, 257, (1989) L163-73.

- [37] M.Y. Aksenov, W.R. Markesbery. Changes in thiol content and expression of glutathione redox system genes in the hippocampus and cerebellum in Alzheimer's disease, *Neurosci Lett*, 302, (2001) 141-5.
- [38] P. Jenner, D.T. Dexter, J. Sian, A.H. Schapira, C.D. Marsden. Oxidative stress as a cause of nigral cell death in Parkinson's disease and incidental Lewy body disease. The Royal Kings and Queens Parkinson's Disease Research Group, *Ann Neurol*, 32 Suppl, (1992) S82-7.
- [39] J.B. Schulz, J. Lindenau, J. Seyfried, J. Dichgans. Glutathione, oxidative stress and neurodegeneration, *Eur J Biochem*, 267, (2000) 4904-11.
- [40] L. Balazs, M. Leon. Evidence of an oxidative challenge in the Alzheimer's brain, *Neurochem Res*, 19, (1994) 1131-7.
- [41] T.L. Perry, V.W. Yong, C. Bergeron, S. Hansen, K. Jones. Amino acids, glutathione, and glutathione transferase activity in the brains of patients with Alzheimer's disease, *Ann Neurol*, 21, (1987) 331-6.
- [42] M.A. Lovell, W.D. Ehmann, S.M. Butler, W.R. Markesbery. Elevated thiobarbituric acid-reactive substances and antioxidant enzyme activity in the brain in Alzheimer's disease, *Neurology*, 45, (1995) 1594-601.
- [43] C. Jeandel, M.B. Nicolas, F. Dubois, F. Nabet-Belleville, F. Penin, G. Cuny. Lipid peroxidation and free radical scavengers in Alzheimer's disease, *Gerontology*, 35, (1989) 275-82.
- [44] R. Perrin, S. Briancon, C. Jeandel, Y. Artur, A. Minn, F. Penin, G. Siest. Blood activity of Cu/Zn superoxide dismutase, glutathione peroxidase and catalase in Alzheimer's disease: a case-control study, *Gerontology*, 36, (1990) 306-13.
- [45] I. Ceballos-Picot, M. Merad-Boudia, A. Nicole, M. Thevenin, G. Hellier, S. Legrain, C. Berr. Peripheral antioxidant enzyme activities and selenium in elderly subjects and in dementia of Alzheimer's type--place of the extracellular glutathione peroxidase, *Free Radic Biol Med*, 20, (1996) 579-87.
- [46] T.R. Hurd, N.J. Costa, C.C. Dahm, S.M. Beer, S.E. Brown, A. Filipovska, M.P. Murphy. Glutathionylation of mitochondrial proteins, *Antioxid Redox Signal*, 7, (2005) 999-1010.
- [47] A.C. Nulton-Persson, D.W. Starke, J.J. Mieyal, L.I. Szweda. Reversible inactivation of alpha-ketoglutarate dehydrogenase in response to alterations in the mitochondrial glutathione status, *Biochemistry*, 42, (2003) 4235-42.
- [48] F. Mastrogiamomo, J.G. Lindsay, L. Bettendorff, J. Rice, S. J. Kish. Brain protein and alpha-ketoglutarate dehydrogenase complex activity in Alzheimer's disease, *Ann of Neurol*, 39, (1996) 592-8.
- [49] G.E. Gibson, H. Zhang, K.F. Sheu, N. Bogdanovich, J.G. Lindsay, L. Lannfelt, M. Vestling, R.F. Cowburn. Alpha-ketoglutarate dehydrogenase in Alzheimer brains bearing

- the APP670/671 mutation, *Ann Neurol*, 44, (1998) 676-81.
- [50] Q. Shi, H.L. Chen, H. Xu, G.E. Gibson. Reduction in the E2k subunit of the alpha-ketoglutarate dehydrogenase complex has effects independent of complex activity, *J Biol Chem*, 280, (2005) 10888-96.
- [51] W.A. Kleinman, D. Komninou, Y. Leutzinger, S. Colosimo, J. Cox, C.A. Lang, J.P. Richie Jr. Protein glutathiolation in human blood, *Biochem Pharmacol*, 65, (2003) 741-6.
- [52] F. Tietze. Enzymic method for quantitative determination of nanogram amounts of total and oxidized glutathione: applications to mammalian blood and other tissues, *Anal Biochem*, 27, (1969) 502-22.
- [53] C.W. Owens, R.V. Belcher. A colorimetric micro-method for the determination of glutathione, *Biochem J*, 94, (1965) 705-11.
- [54] M. Meyer, R. Schreck, P.A. Baeuerle. H<sub>2</sub>O<sub>2</sub> and antioxidants have opposite effects on activation of NF-kappa B and AP-1 in intact cells: AP-1 as secondary antioxidant-responsive factor, *EMBO J*, 12, (1993) 2005-15.
- [55] M.Y. Aksenov, W.R. Markesbery. Changes in thiol content and expression of glutathione redox system genes in the hippocampus and cerebellum in Alzheimer's disease, *Neurosci Lett*, 302, (2001) 141-5.
- [56] P. Jenner, D.T. Dexter, J. Sian, A.H. Schapira, C.D. Marsden. Oxidative stress as a cause of nigral cell death in Parkinson's disease and incidental Lewy body disease. The Royal Kings and Queens Parkinson's Disease Research Group, *Ann Neurol*, 32 Suppl, (1992) S82-7.
- [57] J.B. Schulz, J. Lindenau, J. Seyfried, J. Dichgans. Glutathione, oxidative stress and neurodegeneration, *Eur J Biochem*, 267, (2000) 4904-11.
- [58] J.P. Bolanos, S.J. Heales, S. Peuchen, J.E. Barker, J.M. Land, J.B. Clark. Nitric oxide-mediated mitochondrial damage: a potential neuroprotective role for glutathione, *Free Radic Biol Med*, 21, (1996) 995-1001.
- [59] J.S. Bains, C.A. Shaw. Neurodegenerative disorders in humans: the role of glutathione in oxidative stress-mediated neuronal death, *Brain Res Brain Res Rev*, 25, (1997) 335-58.
- [60] I.S. Kil, J.W. Park. Regulation of mitochondrial NADP<sup>+</sup>-dependent isocitrate dehydrogenase activity by glutathionylation, *J Biol Chem*, 280, (2005) 10846-54.
- [61] R. De Wit, M. Makkinje, J. Boonstra, A.J. Verkleij, J.A. Post. Hydrogen peroxide reversibly inhibits epidermal growth factor (EGF) receptor internalization and coincident ubiquitination of the EGF receptor and Eps15, *FASEB J*, 15, (2001) 306-8.
- [62] J.R. Liddell, H.H. Hoepken, P.J. Crack, S.R. Robinson, R. Dringen. Glutathione peroxidase 1 and glutathione are required to protect mouse astrocytes from iron-mediated hydrogen peroxide toxicity, *J Neurosci Res*, 84, (2006) 578-86.

- [63] P.J. Devine, I.G. Sipes, P.B. Hoyer. Effect of 4-vinylcyclohexene diepoxide dosing in rats on GSH levels in liver and ovaries, *Toxicol Sci*, 62, (2001) 315-20.
- [64] T. Noda, R. Iwakiri, K. Fujimoto, T.Y. Aw. Induction of mild intracellular redox imbalance inhibits proliferation of CaCo-2 cells, *FASEB J*, 15, (2001) 2131-9.
- [65] S.M. Beer, E.R. Taylor, S.E. Brown, C.C. Dahm, N.J. Costa, M.J. Runswick, M.P. Murphy. Glutaredoxin 2 catalyzes the reversible oxidation and glutathionylation of mitochondrial membrane thiol proteins: implications for mitochondrial redox regulation and antioxidant DEFENSE, *J Biol Chem*, 279, (2004) 47939-51.
- [66] H.F. Gilbert. Redox control of enzyme activities by thiol/disulfide exchange, *Methods Enzymol*, 107, (1984) 330-51.
- [67] G.E. Gibson, L.C. Park, K.F. Sheu, J.P. Blass, N.Y. Calingasan. The alpha-ketoglutarate dehydrogenase complex in neurodegeneration, *Neurochem Int*, 36, (2000) 97-112.
- [68] P. Eaton, M.J. Shattock. Purification of proteins susceptible to oxidation at cysteine residues: identification of malate dehydrogenase as a target for S-glutathiolation, *Ann N Y Acad Sci*, 973, (2002) 529-32.
- [69] L. Tretter, V. Adam-Vizi. Inhibition of Krebs cycle enzymes by hydrogen peroxide: A key role of alpha-ketoglutarate dehydrogenase in limiting NADH production under oxidative stress, *J Neurosci*, 20, (2000) 8972-9.
- [70] J.B. Hoek, J. Rydstrom. Physiological roles of nicotinamide nucleotide transhydrogenase, *Biochem J*, 254, (1988) 1-10.

## Figure legends

**Figure 1.** Response of KGDHC and MDH activities to one hr of H<sub>2</sub>O<sub>2</sub>. Values are means ± SEM of specific activity measured from at least three independent experiments in triplicate. Values with different letters differ significantly from each other (P<0.05) as determined by a one-way ANOVA followed by a Student-Newman-Keul's test.

**Figure 2.** Response of mRNA level of cMDH and mMDH to one hr of H<sub>2</sub>O<sub>2</sub>. Quantitative real-time PCR was employed to measure the mRNA levels of cytoplasmic MDH (cMDH) and mitochondrial MDH (mMDH) in the all three lines. Transcript quantitation was measured

relative to  $\beta$ -2-microglobulin amplification from the same sample in parallel. Values in panels A and B are the mean  $\pm$  SEM of fold changes above untreated controls from at least two independent experiments in triplicate. Different letters or numbers in each panel denotes values differ significantly from each other ( $P < 0.05$ ) as determined with a one-way ANOVA followed by a Student-Newman-Keul's test.

**Figure 3.** Glutathionylation of KGDHC by GSSG. Purified KGDHC was incubated with varying concentrations of GSSG followed by SDS-PAGE and Western blotting as described in the Experimental procedures. The blots were probed with antibodies to E1k (A), E2k (B) or E3 (C) (red) and to glutathione (green), respectively. The overlap is represented by yellow.

**Figure 4.** Total free cellular glutathione levels in response to 1 hr of BSO,  $H_2O_2$  or  $H_2O_2$ /BSO. Total free cellular glutathione was measured in the E2k-100, E2k-46 and E2k-23 lines treated with BSO,  $H_2O_2$  or  $H_2O_2$ /BSO for one hr. Values represent the mean  $\pm$  SEM of the total free cellular glutathione (nmole/mg protein) from at least three separate experiments in duplicate. Statistical significance was determined using a one-way ANOVA followed by a Student-Newman-Keul's test. Values with same letters are not significantly different from each other ( $P > 0.05$ ).



**Figure 5.** Response of KGDHC and MDH activities to one hr of BSO,  $H_2O_2$  or  $H_2O_2$ /BSO. Values are the mean  $\pm$  SEM of KGDHC (A) or MDH activity (B) (mU/mg protein) from at least three independent experiments in triplicate. Values with different letters are statistically different from each other ( $P < 0.05$ ) by a one-way ANOVA followed by a Student-Newman-Keul's test.



**Figure 6.** Total free cellular glutathione levels in response to 24 hr of BSO,  $H_2O_2$  or  $H_2O_2$ /BSO. Total free cellular glutathione was measured in the E2k-100, E2k-46 and E2k-23 lines treated with BSO,  $H_2O_2$  or  $H_2O_2$ /BSO for 24 hr. Values represent the mean  $\pm$  SEM of the total free


cellular glutathione (nmole/mg protein) from at least three separate experiments in duplicate. Statistical significance was determined using a one-way ANOVA followed by a Student-Newman-Keul's test. Values with different letters are significantly different from each other ( $P < 0.05$ ).

**Figure 7.** The responses of KGDHC and MDH activities of the E2k-100, E2k-46 and E2k-23 lines to 24 hr of BSO,  $H_2O_2$  or  $H_2O_2$ /BSO. Values are the mean  $\pm$  SEM of KGDHC (A) or MDH activity (B) (mU/mg protein) from at least three independent experiments in triplicate. Values with different letters in each panel are significantly different from each other ( $P < 0.05$ ) as determined with a one-way ANOVA followed by a Student-Newman-Keul's test.


**Figure 8.** Possible interaction of E2k of KGDHC with glutathione. The KGDH complex catalyzes decarboxylation of  $\alpha$ -ketoglutarate, reductive acylation of the lipoyl moiety and reoxidation of the dihydrolipoyl moiety, and generates succinyl-CoA and NADH. E2k contains a lipoyl moiety which is swung between the other two subunits (E1k and E3) during catalysis. The thiol and disulfide of lipoyl moiety cycles during the catalysis.  $E \cdot Lip(SH)(SH)$ ,  $E \cdot Lip(SCOR)(SH)$  and  $E \cdot Lip(S)_2$  are intermediates of E2k subunit during catalysis. Glutathionylation of E2k is only transient as its adjacent thiol displaces the  $GS^-$  to form an intraprotein disulfide (reaction 1). In addition, another E2k intermediate [ $E2k \bullet Lip(SCoR)(SH)$ ] can react with GSSG and form  $E2k \bullet Lip(SCoR)(S-SG)$  (reaction 2) which can further react with [ $E2k \bullet Lip(SCoR)(SH)$ ] to form a disulfide product [ $E2k \bullet Lip(SCoR)(S^-)$ ]<sub>2</sub> (reaction 3).

**Figure 1. Response of KGDHC and MDH activities to 1 hr of H<sub>2</sub>O<sub>2</sub>****A. KGDHC activity****B. MDH activity**


**Figure 2. Response of mRNA level of MDH to 1 hour of H<sub>2</sub>O<sub>2</sub>****A. H<sub>2</sub>O<sub>2</sub> increased mRNA level of cMDH only in the E2k-23 line****B. H<sub>2</sub>O<sub>2</sub> increased mRNA level of mMDH only in the E2k-23 line**


**Figure 3. Glutathionylation of KGDHC by GSSG**

ACCEPTED

**Figure 4. Total free cellular glutathione levels in response to 1 hr of BSO, H<sub>2</sub>O<sub>2</sub> or H<sub>2</sub>O<sub>2</sub>/BSO**

ACCEPTED

Figure 5. Response of KGDHC and MDH activities to 1 hour of BSO, H<sub>2</sub>O<sub>2</sub> or H<sub>2</sub>O<sub>2</sub>/BSO

**Figure 6. Total free cellular glutathione levels in response to 24 hr of BSO, H<sub>2</sub>O<sub>2</sub> or H<sub>2</sub>O<sub>2</sub>/BSO**

ACCEPTED M.



Figure 7. Response of KGDHC and MDH activities to 24 hr of H<sub>2</sub>O<sub>2</sub> or H<sub>2</sub>O<sub>2</sub>/BSO

Figure 8. Possible interaction of E2k of KGDHC with glutathione



ACCEPTED